Cell Division Cycle 7 (CDC7) Related Protein Kinase Market
Cell Division Cycle 7 (CDC7) Related Protein Kinase Market Size, Share & Trends Analysis Report by Type (LBS-007, MSK-777, LY-3143921, TAK-931, and Others), by Application (Solid Tumors, Ovarian Cancer, Colorectal Cancer, Pancreatic Cancer, Hematological Malignancies, Acute Myeloid Leukemia (AML), Lymphomas, and Others), Forecast Period (2026–2035)
Industry Overview
Cell Division Cycle 7 (CDC7) Related Protein Kinase market is anticipated to grow at a considerable CAGR of 15.9% during the forecast period. The market is expanding on account of increasing investment in targeted oncology therapeutics and precision medicine approaches. The rising incidence of complex and treatment-resistant cancers has encouraged the development of novel kinase inhibitors with improved efficacy profiles. Ongoing clinical advancements and a growing pipeline of CDC7 inhibitors are strengthening commercialization prospects across multiple indications. Pharmaceutical companies are actively pursuing strategic collaborations and licensing agreements to accelerate drug development and regulatory approvals. In addition, advancements in molecular biology and biomarker identification are supporting more effective patient stratification, thereby enhancing treatment outcomes and market adoption.
Market Dynamics
Increasing Focus on Targeted Oncology Therapies and CDC7 Inhibition
Rising demand for targeted oncology therapies is a primary factor supporting the growth of the CDC7-related protein kinase market. CDC7 plays a critical role in DNA replication and cell cycle progression, making it a relevant therapeutic target in tumors characterized by high replication stress. The increasing incidence of cancers such as ovarian, colorectal, and hematological malignancies has strengthened the focus on mechanism-driven treatments with improved specificity. Several CDC7 inhibitors are progressing through clinical development, with encouraging efficacy signals in early- and mid-stage trials. Pharmaceutical companies are prioritizing investments in kinase inhibitor pipelines, supported by advances in molecular diagnostics that enable better patient selection. Regulatory pathways for oncology drugs, including accelerated approvals for high unmet needs, are further facilitating development. These factors are contributing to a steady increase in research activity and commercial interest in this segment.
Expansion of Clinical Research and Strategic Industry Collaborations
Expansion of clinical research and strategic industry participation is another key driver influencing market development. A growing number of partnerships, licensing agreements, and research collaborations are enabling access to advanced technologies and accelerating drug discovery timelines. Biopharmaceutical firms are increasingly focusing on combination therapies, where CDC7 inhibitors are evaluated alongside chemotherapy or immunotherapy to enhance treatment response. Improvements in clinical trial design, including adaptive and biomarker-driven studies, are increasing the probability of successful outcomes. In addition, rising healthcare expenditure and stronger emphasis on oncology innovation are supporting funding availability for early-stage assets. Academic institutions and research organizations are also contributing to a deeper understanding of CDC7 biology, which is expanding the scope of potential applications. This collective progress is strengthening the pipeline and supporting future commercialization opportunities.
Market Segmentation
- Based on type, the market is segmented into LBS-007, MSK-777, LY-3143921, TAK-931, and others.
- Based on application, the market is segmented into solid tumors, ovarian cancer, colorectal cancer, pancreatic cancer, hematological malignancies, acute myeloid leukemia (AML), lymphomas, and others.
Lead Molecule Advancing Clinical Momentum
TAK-931 has emerged as the most advanced asset within the CDC7 inhibitor pipeline, supported by its progression into Phase II clinical evaluation for solid tumors. Clinical studies indicate tolerable safety profiles and early signals of antitumor activity, reinforcing its positioning as a leading candidate. The molecule’s mechanism, centered on disrupting DNA replication and inducing replication stress, aligns well with current oncology treatment strategies. Key players such as Takeda and Zai Lab continue to drive development through structured clinical programs and regional collaborations. Increasing focus on oral, targeted small-molecule therapies is further supporting adoption. Recent trends highlight combination approaches with chemotherapy and PARP inhibitors to enhance efficacy across resistant tumor types. This progression is strengthening the commercial outlook for late-stage pipeline candidates.
Expanding Role in Solid Tumor Treatment Landscape
Solid tumors represent the most prominent application area, driven by high disease burden and the need for novel mechanisms targeting replication stress pathways. CDC7 inhibition has demonstrated potential across colorectal, pancreatic, and ovarian cancers, where tumor proliferation rates remain high. Ongoing clinical investigations are increasingly focused on biomarker-driven patient selection to improve response rates and optimize outcomes. Pharmaceutical companies are aligning development strategies toward combination regimens to address therapeutic resistance in advanced-stage cancers. Research institutions and oncology-focused firms are actively contributing to expanding clinical evidence across multiple tumor types. Recent developments show growing integration of CDC7 inhibitors into broader targeted therapy pipelines. This trend is supporting sustained interest and investment in solid tumor indications as a core growth segment.
Regional Outlook
The global cell division cycle 7 (CDC7) related protein kinase market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Established Innovation Hub with Strong Clinical Pipeline Activity
North America continues to lead in the development of CDC7 inhibitors, supported by a well-established biopharmaceutical ecosystem and consistent R&D funding. The presence of major companies such as Takeda and Eli Lilly has strengthened clinical advancement across multiple candidates. Regulatory support for oncology drugs, including expedited pathways for novel therapies, is facilitating faster progression through trial phases. Academic research institutions are actively contributing to translational studies, improving the understanding of kinase targets. Recent trends indicate a shift toward combination-based treatment strategies to enhance therapeutic outcomes. Increasing collaboration between biotech firms and larger pharmaceutical companies is further reinforcing pipeline expansion.
Emerging Research Landscape with Expanding Clinical Participation
Asia Pacific is witnessing steady growth, driven by rising clinical trial activity and increasing investment in oncology research. Countries such as China and Japan are strengthening their role in drug development through supportive regulatory reforms and funding initiatives. Regional players, including Zai Lab, are actively partnering with global firms to accelerate access to innovative therapies. Expanding healthcare infrastructure and growing awareness of targeted treatments are contributing to improved adoption potential. Recent developments show increased participation in multi-center trials, enabling faster patient recruitment and data generation. This evolving landscape is positioning the region as an important contributor to future market growth.
Market Players Outlook
The major companies operating in the global cell division cycle 7 (CDC7) related protein kinase market include Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Carna Biosciences, Inc., Lupin Limited, Schrödinger, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In August 2025, Schrödinger discontinued its CDC7 inhibitor program (SGR-2921) following safety concerns observed during Phase I trials, where patient fatalities were reported.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cell division cycle 7 (CDC7) related protein kinase Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
• Global Cell Division Cycle 7 Related Protein Kinase Market Sales Analysis – By Type | By Application ($ Million)
• Cell Division Cycle 7 Related Protein Kinase Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
• Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Cell Division Cycle 7 Related Protein Kinase Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Cell Division Cycle 7 Related Protein Kinase Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Cell Division Cycle 7 Related Protein Kinase Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Cell Division Cycle 7 Related Protein Kinase Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Cell Division Cycle 7 Related Protein Kinase Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Cell Division Cycle 7 Related Protein Kinase Market Revenue and Share by Manufacturers
- Cell Division Cycle 7 Related Protein Kinase Product Comparison Analysis
• Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 Takeda Pharmaceutical Company Limited
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Eli Lilly and Company
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Carna Biosciences, Inc.
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Lupin Limited
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Schrödinger, Inc.
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Cell Division Cycle 7 Related Protein Kinase Market Sales Analysis by Type ($ Million)
5.1 LBS-007
5.2 MSK-777
5.3 LY-3143921
5.4 TAK-931
5.5 Others
- Global Cell Division Cycle 7 Related Protein Kinase Market Sales Analysis by Application ($ Million)
6.1 Solid Tumors
6.2 Ovarian Cancer
6.3 Colorectal Cancer
6.4 Pancreatic Cancer
6.5 Hematological Malignancies
6.6 Acute Myeloid Leukemia (AML)
6.7 Lymphomas
6.8 Others
- Regional Analysis
9.1 North American Cell Division Cycle 7 Related Protein Kinase Market Sales Analysis – Type | Application | Country ($ Million)
9.1.1 United States
9.1.2 Canada
9.2 European Cell Division Cycle 7 Related Protein Kinase Market Sales Analysis – Type | Application | Country ($ Million)
9.2.1 UK
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 France
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Asia-Pacific Cell Division Cycle 7 Related Protein Kinase Market Sales Analysis – Type | Application | Country ($ Million)
9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 ASEAN Countries
9.3.7 Rest of Asia-Pacific
9.4 Rest of the World Cell Division Cycle 7 Related Protein Kinase Market Sales Analysis – Type | Application | Country ($ Million)
9.4.1 Latin America
9.4.2 Middle East and Africa
- Company Profiles
10.1 AstraZeneca plc
10.1.1 Quick Facts
10.1.2 Company Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.2 BeiGene Ltd.
10.2.1 Quick Facts
10.2.2 Company Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.3 Bristol Myers Squibb Company
10.3.1 Quick Facts
10.3.2 Company Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.4 Carna Biosciences, Inc.
10.4.1 Quick Facts
10.4.2 Company Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.5 Eli Lilly and Company
10.5.1 Quick Facts
10.5.2 Company Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.6 Exelixis, Inc.
10.6.1 Quick Facts
10.6.2 Company Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.7 GlaxoSmithKline plc
10.7.1 Quick Facts
10.7.2 Company Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.8 Hengrui Medicine Co., Ltd.
10.8.1 Quick Facts
10.8.2 Company Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.9 Lupin Limited
10.9.1 Quick Facts
10.9.2 Company Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.10 Memorial Sloan Kettering Cancer Center
10.10.1 Quick Facts
10.10.2 Company Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.11 Merck & Co., Inc.
10.11.1 Quick Facts
10.11.2 Company Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.12 Nerviano Medical Sciences S.r.l.
10.12.1 Quick Facts
10.12.2 Company Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.13 Novartis AG
10.13.1 Quick Facts
10.13.2 Company Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.14 Pfizer Inc.
10.14.1 Quick Facts
10.14.2 Company Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.15 Roche Holding AG
10.15.1 Quick Facts
10.15.2 Company Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.16 Schrödinger, Inc.
10.16.1 Quick Facts
10.16.2 Company Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies
10.17 Takeda Pharmaceutical Company Limited
10.17.1 Quick Facts
10.17.2 Company Overview
10.17.3 Product Portfolio
10.17.4 Business Strategies
10.18 WuXi AppTec Co., Ltd.
10.18.1 Quick Facts
10.18.2 Company Overview
10.18.3 Product Portfolio
10.18.4 Business Strategies
10.19 Zai Lab Limited
10.19.1 Quick Facts
10.19.2 Company Overview
10.19.3 Product Portfolio
10.19.4 Business Strategies
10.20 Cancer Research UK
10.20.1 Quick Facts
10.20.2 Company Overview
10.20.3 Product Portfolio
10.20.4 Business Strategies
1 Global Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Type, 2025–2035 ($ Million)
2 Global LBS-007 Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Region, 2025–2035 ($ Million)
3 Global MSK-777 Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Region, 2025–2035 ($ Million)
4 Global LY-3143921 Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Region, 2025–2035 ($ Million)
5 Global TAK-931 Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Region, 2025–2035 ($ Million)
6 Global Others Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Region, 2025–2035 ($ Million)
7 Global Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Application, 2025–2035 ($ Million)
8 Global Cell Division Cycle 7 Related Protein Kinase for Solid Tumors Market Research and Analysis by Region, 2025–2035 ($ Million)
9 Global Cell Division Cycle 7 Related Protein Kinase for Ovarian Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
10 Global Cell Division Cycle 7 Related Protein Kinase for Colorectal Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
11 Global Cell Division Cycle 7 Related Protein Kinase for Pancreatic Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
12 Global Cell Division Cycle 7 Related Protein Kinase for Hematological Malignancies Market Research and Analysis by Region, 2025–2035 ($ Million)
13 Global Cell Division Cycle 7 Related Protein Kinase for Acute Myeloid Leukemia (AML) Market Research and Analysis by Region, 2025–2035 ($ Million)
14 Global Cell Division Cycle 7 Related Protein Kinase for Lymphomas Market Research and Analysis by Region, 2025–2035 ($ Million)
15 Global Cell Division Cycle 7 Related Protein Kinase for Others Market Research and Analysis by Region, 2025–2035 ($ Million)
16 Global Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Region, 2025–2035 ($ Million)
17 North America Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Country, 2025–2035 ($ Million)
18 North America Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Type, 2025–2035 ($ Million)
19 North America Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Application, 2025–2035 ($ Million)
20 Europe Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Country, 2025–2035 ($ Million)
21 Europe Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Type, 2025–2035 ($ Million)
22 Europe Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Application, 2025–2035 ($ Million)
23 Asia-Pacific Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Country, 2025–2035 ($ Million)
24 Asia-Pacific Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Type, 2025–2035 ($ Million)
25 Asia-Pacific Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Application, 2025–2035 ($ Million)
26 Rest of the World Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Region, 2025–2035 ($ Million)
27 Rest of the World Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Type, 2025–2035 ($ Million)
28 Rest of the World Cell Division Cycle 7 Related Protein Kinase Market Research and Analysis by Application, 2025–2035 ($ Million)
1 Global Cell Division Cycle 7 Related Protein Kinase Market Share by Type, 2025 Vs 2035 (%)
2 Global LBS-007 Cell Division Cycle 7 Related Protein Kinase Market Share by Region, 2025 Vs 2035 (%)
3 Global MSK-777 Cell Division Cycle 7 Related Protein Kinase Market Share by Region, 2025 Vs 2035 (%)
4 Global LY-3143921 Cell Division Cycle 7 Related Protein Kinase Market Share by Region, 2025 Vs 2035 (%)
5 Global TAK-931 Cell Division Cycle 7 Related Protein Kinase Market Share by Region, 2025 Vs 2035 (%)
6 Global Others Cell Division Cycle 7 Related Protein Kinase Market Share by Region, 2025 Vs 2035 (%)
7 Global Cell Division Cycle 7 Related Protein Kinase Market Share by Application, 2025 Vs 2035 (%)
8 Global Cell Division Cycle 7 Related Protein Kinase for Solid Tumors Market Share by Region, 2025 Vs 2035 (%)
9 Global Cell Division Cycle 7 Related Protein Kinase for Ovarian Cancer Market Share by Region, 2025 Vs 2035 (%)
10 Global Cell Division Cycle 7 Related Protein Kinase for Colorectal Cancer Market Share by Region, 2025 Vs 2035 (%)
11 Global Cell Division Cycle 7 Related Protein Kinase for Pancreatic Cancer Market Share by Region, 2025 Vs 2035 (%)
12 Global Cell Division Cycle 7 Related Protein Kinase for Hematological Malignancies Market Share by Region, 2025 Vs 2035 (%)
13 Global Cell Division Cycle 7 Related Protein Kinase for Acute Myeloid Leukemia (AML) Market Share by Region, 2025 Vs 2035 (%)
14 Global Cell Division Cycle 7 Related Protein Kinase for Lymphomas Market Share by Region, 2025 Vs 2035 (%)
15 Global Cell Division Cycle 7 Related Protein Kinase for Others Market Share by Region, 2025 Vs 2035 (%)
16 Global Cell Division Cycle 7 Related Protein Kinase Market Share by Region, 2025 Vs 2035 (%)
17 United States Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
18 Canada Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
19 UK Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
20 France Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
21 Germany Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
22 Italy Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
23 Spain Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
24 Russia Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
25 India Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
26 China Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
27 Japan Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
28 South Korea Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
29 Australia & New Zealand Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
30 ASEAN Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
31 Rest of Asia-Pacific Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
32 Latin America Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
33 Middle East & Africa Cell Division Cycle 7 Related Protein Kinase Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
